Et D2, Brute?

The three erectile dysfunction drugs on the market in the U.S. are phosphodiesterase-5 (PDE-5) inhibitors, which act in the periphery. Instead of playing in this now-crowded space, Abbott Laboratories has focused its ED program on the central nervous system, and has brought its Uprima apomorphine non-selective dopamine agonist to market in Europe. ABT's next entry is ABT-724, a selective dopamine D4 receptor agonist that the company hopes will avoid the side effects of apomorphine and prove attractive to a partner who wants to play in the ED space.

Dopamine receptors are expressed in multiple regions of the CNS, such as the cortex and hypothalamus, and are thought to promote erection via nitric oxide-based relaxation, vasodilation and engorgement of the penis. ...